Skip to main content

Expansion of Cell-to-Cell Communication Drives the Early Development of Pancreatic Cancer, New Research in Mice Finds




Press & Communications Section Head
Tel.+34 93 40 37255

Discussions of cancer often stress the genetic mutations that drive disease by altering the normal function of cellular proteins. KRAS, for example, normally acts as an on/off switch for cellular proliferation, but mutations to the gene — common in lung cancer, colorectal cancer and pancreatic cancer — cause that switch to stay on.

Yet mutations are only half of the story.

Interactions between these genetic mutations and external factors, such as tissue injury that leads to inflammation, reshape both cells’ identities and their local environment in ways that foster cancer’s emergence and runaway growth.

In pancreatic cancer, these changes start to happen fast — within 24 to 48 hours after tissue damage. They happen predictably. And they greatly expand some cells’ ability to communicate and interact with nearby cells.


Those were the findings from a new study published May 11 in Science by an international research team lead by investigators at Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) and Dr. Direna Alonso-Curbelo at IRB Barcelona. The research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.

While the five-year survival rate for pancreatic cancer has been inching upward in recent years, it remains quite low — just 12%, according to the Pancreatic Cancer Action Network. The disease is usually not caught until the cancer is in advanced stages and, thanks in part to advances in treating other types of cancer, pancreatic cancer is the third-leading cause of cancer-related death.

The research aimed not only to shed light on the difficult-to-study early cellular events that give rise to pancreatic cancer, but also to find potential opportunities for medical intervention at earlier stages of the disease.

How Plasticity Drives Cancer

The ability for cells to shed their original identity and adapt is called plasticity. And this plasticity is enhanced by inflammation, the researchers found.


“These precancerous cells gain the ability to send and receive far more signals than a normal cell,” says computational biologist Dr. Dana Pe’er, one of the paper’s two senior authors. “And we saw that this isn’t random — it’s structured. You see the same patterns emerge over and over when you run the experiments in different mice.”

The study was led by co-first authors Cassandra Burdziak, a doctoral student in the Pe’er Lab, and Dr. Direna Alonso-Curbelo, PhD., a former member of the lab of co-senior author Scott Lowe, PhD, who now leads her own lab at IRB Barcelona.
In order to study the origins and impacts of plasticity on cells expressing a mutated version of KRAS, the scientists performed single-cell analyses on normal, inflamed, premalignant and malignant tissues using a genetically engineered mouse model designed to accurately recreate many aspects of pancreatic cancer in humans — from its beginning to metastasis.


"These models allowed us to capture the earliest changes in pancreatic epithelial cells as they progressed from a healthy state toward a malignant state,” says Dr. Lowe, a Howard Hughes Medical Institute Investigator and Chair of the Cancer Biology and Genetics Program at the Sloan Kettering Institute. The single-cell analyses allowed researchers to tease apart the characteristics of sub-populations of individual cells within the pancreas at each stage of progression and how their interactions further drive the progression.

“This project required a significant amount of computational innovation, most of it led by Cassandra,” notes Pe’er, who is also a Howard Hughes Medical Institute Investigator and who heads the Computational and Systems Biology Program at the Sloan Kettering Institute. “We had to invent a number of new methods to answer questions that aren’t typically asked about plasticity, cell-to-cell communication, and tumor progression.”

For example, the team invented a new classification score to measure the plasticity of a cell. The team also found increased plasticity led to the enhancement of genes related to cell-to-cell communication: like those that encode ligands and receptors.

“Basically, these are genes that enable cells to send and receive signals from its environment and with other cells,” Dr. Pe’er says. “This gives the cell the ability to respond to signals that a normal cell wouldn’t be able to. They also have an enhanced ability to communicate with immune cells, and, as a result, the immune system around these cells starts to change.”

Additionally, the researchers were able to determine that a few sub-populations of cells, some of them quite rare, transform into major hubs of communication, driving a feedback loop that leads to the development and progression of pancreatic cancer.

The study represents the culmination of research initiated by Dr. Alonso-Curbelo, who has a long-standing interest in detailing the molecular mechanism by which inflammation promotes cancer initiation.


“This work was a true partnership between experimental science and computational science,” Dr. Alonso-Curbelo says.

Computational models were validated with follow-up experiments. “For example, imaging showed us that the populations of cells that computational methods said were talking to each other were significantly closer to each other in the tissue,” Burdziak says.

Through further experiments, the team was able to demonstrate that these conversations drive cancer development.


“We developed new mouse models to specifically block cell-to-cell signaling associated with neoplastic plasticity,” Dr. Alonso-Curbelo says. “These analyses showed that these expansive communication networks direct pancreatic tumor formation in the mice.“

Toward Clinical Applications

As a whole, the research provides a new, detailed understanding of how cells carrying a mutated copy of the KRAS gene gain plasticity and drive the progression of cancer when subjected to inflammation.

“This provides a roadmap that can help develop strategies to detect or possibly even prevent pancreatic tumors before they reach an incurable stage,” Dr. Lowe says. “And understanding how cell-to-cell communication networks drive the initiation of pancreatic cancer holds promise for the development of therapeutics to block or slow early cancer progression, and even potentially more advanced disease.”

This work was supported by Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center at MSK, the National Cancer Institute (P30 CA008748, F31CA24690, U54 CA209975), a La Caixa Junior Leader Fellowship (LCF/BQ/PI20/11760006), a FERO-ASEICA grant, the Spanish Ministry of Science and Innovation (PID2021-128102OA-I00), an Edward P. Evans Young Investigator Award, a fellowship from the DKFZ Clinician Scientist Program, supported by the Dieter Morszeck Foundation, the Fraser Memorial Trust, a McGill MI4 Platform grant, Howard Hughes Medical Institute Fellowship of the Damon Runyon Cancer Research Foundation (DRG-2382-19), the National Institutes of Health (R25 CA233208), the Howard Hughes Medical Institute, Geoffrey Beene, the National Institute of Child Health and Human Development (HD084071), and the Starr Cancer Consortium.


Related article:

Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis
Cassandra Burdziak†, Direna Alonso-Curbelo†, Thomas Walle, José Reyes, Francisco M. Barriga, Doron Haviv, Yubin Xie, Zhen Zhao, Chujun Julia Zhao, Hsuan-An Chen, Ojasvi Chaudhary, Ignas Masilionis, Zi-Ning Choo, Vianne Gao, Wei Luan, Alexandra Wuest, Yu-Jui Ho, Yuhong Wei, Daniela F. Quail, Richard Koche, Linas Mazutis, Ronan Chaligné, Tal Nawy, Scott W. Lowe*, Dana Pe’er*    
†Equal contribution
Science (2022) DOI: 10.1126/science.add5327


Source: Memorial Sloan Kettering Cancer Center

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).